2020 CMHC West Accreditation
May 1-3, 2020 | Scottsdale, AZ
4th Annual CMHC West
May 1-3, 2020 | Scottsdale, AZ
CMHC West is designed for US-based healthcare professionals, including primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, and other allied health professionals.
STATEMENT OF NEED/PROGRAM OVERVIEW
The ever-increasing presence of cardiometabolic risk continues to be a major challenge for health care providers in the United States. Current estimates suggest approximately 23% - 38% of all U.S. adults have metabolic syndrome, a constellation of cardiometabolic risk factors, including excessive abdominal fat, insulin resistance, inflammation, dyslipidemia, and hypertension. Patients with multiple cardiometabolic risk factors have twice the likelihood of developing and dying from cardiovascular disease and more than seven times the risk of developing diabetes compared to those with no cardiometabolic risk factors. Cardiovascular disease already affects approximately 83.6 million U.S. adults (> 1 in 3) and is the leading cause of U.S. deaths; however, this CVD burden can be expected to increase.
This sampling of sobering statistics points to a rapidly growing epidemic of cardiovascular and metabolic disease and calls to the forefront the need for medical education focused on all aspects of cardiometabolic risk. The CMHC presents an especially valuable venue for this educational outreach with sessions fostering a collaborative, multidisciplinary approach to care.
The 2020 CMHC West meeting will highlight the latest updates in hypertension, heart failure, diabetes, dyslipidemia, lifestyle management, bariatric surgery, and cardiovascular health, and translate the latest cutting-edge medical research into practical, clinical strategies for preventing, delaying, and managing cardiovascular and metabolic disorders.
New to this year is a one-day summit that will explore the unique challenges faced by clinicians when comprehensively managing patients with cardiometabolic disease. The summit will be kicked off with a series of keynote talks to set the stage about what clinicians need to evaluate and address in their patients, how to synthesize and apply what we have learned to date about both primary and secondary prevention to optimize patient outcomes, and including the patient in clinical decision-making.
The talks will be followed by a unique opportunity to interact with our expert panel. This part of the summit is designed to be highly interactive and give the participants extensive opportunity to participate and highlight challenges and solutions to real-world care for their patients.
After completing this activity, the participant should be better able to:
List current and updated evidence-based guideline recommendations for prevention, screening, and treatment of cardiometabolic disease and comorbidities
Discuss the cardiovascular benefits and risks of bariatric surgery, pharmacotherapy, and lifestyle modifications for weight management in patients with cardiometabolic disease and T2DM
Analyze the most recent clinical trial data for the management and treatment of complex patients with hypertension, heart failure, dyslipidemia, and type 2 diabetes mellitus
Develop individualized treatment regimens for cardiometabolic diseases based on efficacy and safety of current, new, and emerging pharmacotherapies, benefits of lifestyle modifications, and patient profiles and preferences to optimize patient outcomes
Please click here to view all faculty listings.
Please click here to view the full agenda.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and CMHC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
*credit amount subject to change
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of *14.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for *14.5 contact hour(s) (1.45 CEUs) of the Accreditation Council for Pharmacy Education.
This is an application-based activity. Universal Activity Number (UAN) will be provided.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is *14.5 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.
CONTINUING DIETICIAN education
Postgraduate Institute for Medicine (CDR Provider #3631) is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive *14.5 Continuing Professional Education units (CPEUs) for completion of this activity.
This is a Level III activity.
ABIM MOC CERTIFICATION
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to *14.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
A full listing of faculty disclosures will be provided.
Planners and Managers
The PIM planners and managers have nothing to disclose. The CMHC planners and managers have nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Request for Credit
Information to come.
FEE INFORMATION & REFUND/CANCELLATION POLICY
There is registration fee for this educational activity, registration information can be found here.